GARDEN CITY, NY - 目前市值1280万美元的生物科技和消费品公司ProPhase Labs, Inc.（NASDAQ: PRPH）宣布实施战略性成本削减措施，并将重点放在直接面向消费者（DTC）营销计划上，以推动增长和盈利。该公司最近出售了其Pharmaloz Manufacturing子公司，正在精简运营，专注于其高增长核心业务，包括BE-Smart食管癌诊断和Nebula ...

GARDEN CITY, NY - 专注于生物科技、基因组学和消费品的ProPhase Labs, Inc.（纳斯达克代码：PRPH）今日宣布任命Stu Hollenshead为首席运营官。根据 InvestingPro 数据显示，该公司目前市值为$7.76百万，正面临重大运营挑战，此次任命是公司加强消费者健康和保健产品战略布局的一部分。

The firm’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $1.42. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48. A number of hedge ...

Tuesday named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into ...

ProPhase Labs, Inc., a company specializing in pharmaceutical preparations with a current market capitalization of $8.16 million, has announced an executive shift with the departure of its current ...

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...

ProPhase Labs February 2025 Update Note Highlights ... The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor SummitDate ...

Meanwhile, the company has disclosed a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its stock has traded below the required $1.00 threshold. ProPhase Labs ...

ProPhase Labs (PRPH) provides a Company update and schedules a conference call. Following the hiring of Stu Hollenshead, several new strategic ...

ProPhase Labs, Inc. GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer ...